Dapagliflozin (Farxiga®) Tablets for Diabetes, Heart Failure, CKD

What Dapagliflozin Is and How It Works

Dapagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor. This class lowers blood glucose by blocking glucose reabsorption in the kidneys. More glucose is excreted in the urine, which can also reduce body weight and blood pressure. It is supplied as tablets in 5 mg and 10 mg strengths. Common uses include type 2 diabetes, chronic kidney disease, and heart failure risk reduction. Many people search for dapagliflozin tablets and the dapagliflozin 10 mg tablet for these approved uses. CanadianInsulin is a prescription referral service. Prescriptions are verified with your clinic, and orders are filled by licensed Canadian pharmacies.

For type 2 diabetes, dapagliflozin helps lower A1C as add‑on therapy to diet and exercise. It may be used alone or with metformin, insulin, or other agents. For heart failure, it reduces the risk of hospitalization, including in patients without diabetes. For chronic kidney disease, it slows decline in kidney function and lowers the risk of kidney failure and cardiovascular death. Patients and clinicians may consider the 10 mg strength for heart failure and CKD indications, while 5 mg is a typical starting dose for glycemic control.

Learn more about related conditions in Type 2 Diabetes, Heart Failure, and Kidney Disease categories.

Dosage and Usage

• Typical starting dose for type 2 diabetes: 5 mg once daily in the morning. May increase to 10 mg once daily if tolerated and additional control is needed.
• Heart failure or chronic kidney disease indications: 10 mg once daily is commonly used.
• Take with or without food. Morning dosing may reduce nocturia for some patients.
• Assess kidney function before starting and during therapy. Do not use in patients on dialysis.
• Volume status matters. Consider correcting dehydration before starting to reduce hypotension risk.
• Missed dose: take when remembered the same day. Skip if close to the next dose. Do not double doses.
• Before surgery or prolonged fasting, clinicians may hold dapagliflozin for 3 days to lower ketoacidosis risk.

• Storage: keep tablets at 20–25°C (68–77°F). Excursions 15–30°C (59–86°F) are allowed.
• Protect from moisture. Store in the original container with the desiccant if present.
• Keep out of reach of children and pets.
• Travel: carry in original labeled packaging. Keep in carry‑on luggage and avoid extreme heat (do not leave in a hot car).
• Do not use tablets past the labeled expiration date.

Benefits and Savings

Dapagliflozin helps reduce A1C by about 0.5–1.0% when added to baseline therapy. Many patients see modest weight loss, often 2–3 kg over time. Systolic blood pressure reductions of 3–5 mmHg are common. In heart failure, it lowers the risk of hospitalization and can improve symptoms. In CKD, it slows eGFR decline and reduces progression to kidney failure.

Convenience is another benefit. A once‑daily tablet suits many routines and combines well with metformin, insulin, GLP‑1 receptor agonists, or DPP‑4 inhibitors. For those comparing the dapagliflozin 10 mg price to branded options, generic availability often reduces out‑of‑pocket cost. Many customers save 60–80% vs typical U.S. prices.

See our promotions page for current offers, including any dapagliflozin coupon if available.

Side Effects and Safety

• Genital yeast infections (more common in females and uncircumcised males)
• Urinary tract infections and increased urination
• Thirst, dry mouth, or dehydration
• Dizziness or low blood pressure, especially in volume depletion
• Nausea or abdominal discomfort
• Back pain, nasopharyngitis, or headache
• Increases in LDL cholesterol may occur

Serious risks are uncommon but include ketoacidosis (even with normal glucose), severe urinary infections, Fournier’s gangrene, acute kidney injury in susceptible patients, and severe allergic reactions. Hypoglycemia risk increases when used with insulin or sulfonylureas; clinicians may lower background doses to reduce this risk. Use caution in patients with frequent UTIs, volume depletion, or history of genital mycotic infections. Avoid use in pregnancy, especially in the second and third trimesters, and do not use in patients on dialysis.

Onset Time

Blood glucose effects begin within the first 1–2 weeks, with A1C changes accumulating over 12–24 weeks as dosing stabilizes. Weight changes usually emerge over 4–12 weeks and can continue gradually with ongoing therapy. In heart failure, benefits on symptoms and reduced hospitalization risk can appear within weeks. Kidney outcomes are tracked over months to years, with early stabilization in eGFR slope often seen after initiation.

Compare With Alternatives

Dapagliflozin is the generic of Farxiga®. Patients who need brand labeling can consider the branded option; see Farxiga Dapagliflozin for details. The active ingredient is the same.

Other SGLT2 inhibitors include empagliflozin (Jardiance®) and canagliflozin (Invokana®). All reduce blood glucose and provide cardiovascular and kidney benefits, though trial populations and labeling differ. Choice often depends on comorbidities, eGFR thresholds, and tolerability.

Another path is a GLP‑1 receptor agonist such as Trulicity® or oral semaglutide (Rybelsus®). These agents lower A1C and support weight loss, and they combine well with SGLT2 inhibitors when appropriate. For glycemic management, some patients use dapagliflozin with a GLP‑1 RA to target both fasting and post‑meal glucose.

Combination Therapy

• With metformin for foundational type 2 diabetes management.
• With insulin or sulfonylureas; consider reducing background doses to limit hypoglycemia.
• With GLP‑1 receptor agonists for additional A1C and weight benefits.
• With ACE inhibitors or ARBs in CKD for kidney protection.
• Use caution with loop or thiazide diuretics due to volume depletion risk; monitor blood pressure and renal function.

Patient Suitability and Cost‑Saving Tips

Candidates include adults with type 2 diabetes needing additional glycemic control, patients with symptomatic heart failure (reduced or preserved ejection fraction) to reduce hospitalization risk, and patients with chronic kidney disease to slow progression. It is not for type 1 diabetes due to ketoacidosis risk. It should not be used in dialysis. Those with active genital infections, recurrent UTIs, severe dehydration, or hypersensitivity to dapagliflozin may not be suitable. Use caution in older adults and in those on diuretics or with low blood pressure.

Cost‑saving tips include choosing generic dapagliflozin when appropriate, considering a multi‑month supply, and aligning refills to reduce shipping frequency. Comparing the dapagliflozin price by strength and quantity can help match budget needs. CanadianInsulin works with licensed and vetted partner pharmacies to provide authentic medications, a broad selection, and value‑focused pricing with prompt, express, cold‑chain shipping.

Authoritative Sources

AstraZeneca Farxiga Prescribing Information

Health Canada Product Monograph: Forxiga (dapagliflozin)

FDA Label: Dapagliflozin Tablets

Order Dapagliflozin from CanadianInsulin: add to cart, upload your prescription, and we ship with prompt, express, cold‑chain handling.

This page is for educational purposes and does not replace professional medical advice. Always consult a qualified healthcare provider about diagnosis, treatment, and medication choices.